Biosimilars Council urges SCOTUS to limit biologics exclusivity period

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), has filed a brief in support of Sandoz’s petition for certiorari in the pending Sandoz v Amgen case.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Dow asks SCOTUS to review $445m award dispute

15 September 2017 Agriculture company Dow has asked the US Supreme Court to review a dispute centring on damages for infringement of patents related to genetically engineered soybeans.

Americas

Fed Circuit erred in Sandoz v Amgen, says solicitor general

28 February 2017 The US Court of Appeals for the Federal Circuit erred in holding that biosimilar applicants must give 180 days’ pre-marketing notice after an application has been approved by the US Food and Drug Administration, according to the acting solicitor general.

More on this story

Americas

Dow asks SCOTUS to review $445m award dispute

15 September 2017 Agriculture company Dow has asked the US Supreme Court to review a dispute centring on damages for infringement of patents related to genetically engineered soybeans.

Americas

Fed Circuit erred in Sandoz v Amgen, says solicitor general

More on this story

Americas

Dow asks SCOTUS to review $445m award dispute

15 September 2017 Agriculture company Dow has asked the US Supreme Court to review a dispute centring on damages for infringement of patents related to genetically engineered soybeans.

Americas

Fed Circuit erred in Sandoz v Amgen, says solicitor general